The CEO and CMO selling at $9.01-28% below the May 7 offering price of $11.52, suggests insiders see limited near-term upside post-dilution and post-catalyst. Monitor for additional insider selling in the next 30 days; if C-suite continues to sell, it would reinforce a bearish read. The $300M cash raise funds operations into Q2 2027, but the stock's post-offering slide indicates the market is pricing in heavy dilution.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 20 $7.84entry
- T+1 · 6mo ago +1.91%α +1.72% · $7.99
- T+5 · 6mo ago −2.93%α −4.74% · $7.61
- T+20 · 5mo ago +25.26%α +24.51% · $9.82
- T+60 · due 3mo ago Pending
Price Chart
How similar events traded
Executive Summary
CEO Fred Aslan and CMO Subhashis Banerjee sold a combined $308K in open-market sales on May 19, 2026, just 11 days after a $300M dilutive offering priced at $11.52/share and 12 days after positive Phase 2a RA data. The sales are small relative to the $228M market cap (0.14%), but the timing, immediately after a large secondary and at a price ($9.01) well below the offering price, raises concern that insiders are reducing exposure post-dilution and post-catalyst. The cluster is amplified by the cross-filing context of a recent capital raise and earnings release.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 27,116 shares for $244K on May 19, 2026 at $9.01
- CMO Subhashis Banerjee sold 7,037 shares for $63K on May 19, 2026 at $9.01
- President Diego Miralles received 310,000 shares via non-cash grants on May 18, 2026 ($0 value)
- Total open-market sales: $308K, representing 0.14% of $228M market cap
- Sales occurred 11 days after a $300M dilutive offering at $11.52/share and 12 days after positive Phase 2a RA data
- Stock price has declined from $12.52 (May 7) to $9.01 (May 19), a 28% drop
Financial Impact
Insider sales of $308K (0.14% of market cap) are modest in absolute terms but notable for timing and price level
Risk Factors
- Further insider selling could signal deteriorating confidence in near-term catalysts
- The $300M offering at $11.52 created massive dilution (26M shares, ~50% of pre-offer float), pressuring the stock
- Pre-revenue biotech with cash burn of ~$23.5M/quarter; positive Phase 2a data may not translate to Phase 3 success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1779241868981 |
Track record
33 reports on ARTV
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers